ADITXT INC (ADTX)

US0070256047 - Common Stock

0.3299  -0.07 (-17.53%)

After market: 0.325 0 (-1.49%)

News Image
12 hours ago - Chartmill

Which stocks are moving before the opening bell on Tuesday?

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

News Image
12 days ago - Evofem Biosciences, Inc.

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third...

News Image
2 months ago - Invezz

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]

News Image
3 months ago - Invezz

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate Cancer

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc., has submitted a grant application to the Prostate Cancer Research Program (“PCRP”) under the Department of Defense (“DoD”) Implementation Science Award funding mechanism. Pearsanta is seeking $2 million in non-dilutive funding to advance the […]

News Image
3 months ago - Evofem Biosciences, Inc.

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

/PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc....

News Image
3 months ago - InvestorPlace

ADTX Stock Earnings: Aditxt Reported Results for Q2 2024

Aditxt just reported results for the second quarter of 2024.

News Image
3 months ago - BusinessInsider

ADTX Stock Earnings: Aditxt Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aditxt (NASDAQ:ADTX) just reported results for the second quarter of 2024.Aditx...

News Image
3 months ago - Invezz

BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and […]

News Image
3 months ago - Evofem Biosciences, Inc.

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second...